{"nctId":"NCT02374060","briefTitle":"PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial","startDateStruct":{"date":"2015-06-16","type":"ACTUAL"},"conditions":["Macular Edema","Uveitis"],"count":192,"armGroups":[{"label":"Periocular triamcinolone 40mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Periocular triamcinolone 40 mg"]},{"label":"Intravitreal triamcinolone 4mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Intravitreal triamcinolone 4 mg"]},{"label":"Dexamethasoneintravitreal implant","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Dexamethasone intravitreal implant"]}],"interventions":[{"name":"Periocular triamcinolone 40 mg","otherNames":["Kenalog"]},{"name":"Intravitreal triamcinolone 4 mg","otherNames":["Triescence (in U.S); Kenalog allowed at non-U.S. clinics"]},{"name":"Dexamethasone intravitreal implant","otherNames":["Ozurdex"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nEye level inclusion criteria - at least one eye must meet all of the following conditions:\n\n* Non-infectious anterior, intermediate, posterior or panuveitis; either active or inactive uveitis is acceptable;\n* Macular edema (ME) defined as the presence of central subfield macular thickness greater than the normal range for the OCT machine being used, regardless of the presence of cysts, as assessed by study ophthalmologist;\n* Best corrected visual acuity (BCVA) 5/200 or better;\n* Baseline intraocular pressure \\> 5 mm Hg and ≤ 21 mm Hg (current use of 3 or fewer intraocular pressure-lowering medications and/or prior glaucoma surgery are acceptable);\n* Baseline fluorescein angiogram that is gradable for leakage in the central subfield\n* Pupillary dilation sufficient to allow OCT testing.\n\nExclusion Criteria:\n\nPatient level exclusion criteria:\n\n-History of infectious uveitis, or of scleritis, keratitis, or infectious endophthalmitis in either eye;\n\nHistory of central serous retinopathy in either eye;\n\n* For women of childbearing potential: pregnancy, breastfeeding, or a positive pregnancy test; unwilling to practice an adequate birth control method (abstinence, combination barrier and spermicide, or hormonal) for duration of trial;\n* Use of oral acetazolamide or other systemic carbonic anhydrase inhibitor at baseline;\n* Oral prednisone dose \\> 10 mg per day (or of an alternative corticosteroid at a dose higher than that equipotent to prednisone 10 mg per day) OR oral prednisone dose ≤ 10 mg per day that has not been stable for at least 4 weeks(note that if patient is off of oral prednisone at baseline (P01 visit), dose stability requirement for past 4 weeks does not apply);\n* Systemic immunosuppressive drug therapy that has not been stable for at least 4 weeks;\n* Known allergy or hypersensitivity to any component of the study drugs;\n\nEye level exclusion criteria - at least one eye that meets all inclusion criteria cannot have any of the following conditions:\n\n* History of severe glaucoma as defined by optic nerve damage (cup/disc ratio of ≥ 0.9 or any notching of optic nerve to the rim);\n* Media opacity causing inability to assess fundus or perform OCT;\n* Presence of an epiretinal membrane noted clinically or by OCT that per the judgment of study ophthalmologist may be significant enough to limit improvement of ME (i.e., causing substantial wrinkling of the retinal surface)81;\n* Torn or ruptured posterior lens capsule;\n* Presence of silicone oil;\n* Periocular or intravitreal corticosteroid injection in past 8 weeks;\n* Injection of dexamethasone intravitreal implant in past 12 weeks;\n* Placement of fluocinolone acetonide implant (Retisert) in past 3 years;","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Baseline Central Subfield Thickness Observed at 8 Weeks","description":"The primary outcome is the change in central subfield thickness from baseline to 8 weeks measured on a relative scale as the the proportion of the baseline central subfield thickness. Values less than 1 indicate a decrease in retinal thickness with lower values indicating greater decreases. Smaller values are better.\n\nThe time point of 8 weeks was chosen for assessment of the primary outcome because it encompasses the window for maximum benefit for all three treatment strategies. Retinal thickness was evaluated using masked assessments of OCT images.","paramType":"MEAN","dispersionType":"99.87% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".77","spread":null},{"groupId":"OG001","value":".61","spread":null},{"groupId":"OG002","value":".54","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Baseline Central Subfield Thickness Observed at 24 Weeks","description":"The primary outcome is the change in central subfield thickness from baseline to 24 weeks measured on a relative scale as the the proportion of the baseline central subfield thickness. Values less than 1 indicate a decrease in retinal thickness with lower values indicating greater decreases. Smaller values are better.The time point of 24 weeks was chosen to evaluate the duration of response and the need for additional injections.Retinal thickness was evaluated using masked assessments of OCT images.","paramType":"MEAN","dispersionType":"99.87% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.68","spread":null},{"groupId":"OG001","value":"0.64","spread":null},{"groupId":"OG002","value":"0.61","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Eyes With >= 20% Reduction in Macular Thickness (or Normalization Even if <20% Reduction) at 8 Weeks","description":"Proportion of eyes with \\>=20% reduction in macular thickness (or normalization of macular thickness even if there is \\<20% reduction) at 8 weeks.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.41","spread":null},{"groupId":"OG001","value":"0.79","spread":null},{"groupId":"OG002","value":"0.84","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Eyes With >= 20% Reduction in Macular Thickness (or Normalization Even if <20% Reduction) at 24 Weeks","description":"Proportion of eyes with \\>=20% reduction in macular thickness (or normalization of macular thickness even if there is \\<20% reduction) at 24 weeks","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.61","spread":null},{"groupId":"OG001","value":"0.73","spread":null},{"groupId":"OG002","value":"0.74","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Eyes With Resolution of Macular Edema at 8 Weeks","description":"Proportion of eyes with resolution of macular edema defined as normalization of the macular thickness (i.e., \\< 260 um on the standardized scale) at 8 weeks. The greater the proportion the more eyes achieved resolution of macular edema.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.20","spread":null},{"groupId":"OG001","value":"0.47","spread":null},{"groupId":"OG002","value":"0.61","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Eyes With Resolution of Macular Edema at 24 Weeks","description":"Proportion of eyes with resolution of macular edema defined as normalization of the macular thickness (i.e., \\<260 um on the standard scale) at 24 weeks.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":null},{"groupId":"OG001","value":"0.36","spread":null},{"groupId":"OG002","value":"0.41","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Best-corrected Visual Acuity at 8 Weeks","description":"Mean change in best-corrected visual acuity from baseline to 8 weeks. Participants' visual acuity was measured by certified examiners with best refractive correction in place.Participants were challenged with reading letters on lines of the standard ETDRS eye chart (5 letters per line). Lines became smaller as participants progressed from the top to the bottom of the chart. Participants read down the chart until no more meaningful readings could be made and were scored by how many letters could be correctly identified. More letters read is associated with higher visual acuity.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.37","spread":null},{"groupId":"OG001","value":"9.70","spread":null},{"groupId":"OG002","value":"9.53","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Best-corrected Visual Acuity at 24 Weeks","description":"Mean change in best-corrected visual acuity from baseline to 24 weeks. Participants' visual acuity was measured by certified examiners with best refractive correction in place.Participants were challenged with reading letters on lines of the standard ETDRS eye chart (5 letters per line). Lines became smaller as participants progressed from the top to the bottom of the chart. Participants read down the chart until no more meaningful readings could be made and were scored by how many letters could be correctly identified. More letters read is associated with higher visual acuity.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.07","spread":null},{"groupId":"OG001","value":"9.60","spread":null},{"groupId":"OG002","value":"9.21","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Eyes With Vitreous Hemorrhage","description":"Count of eyes with vitreous hemorrhage as an immediate complication of injection.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Eyes With Retinal Tear or Detachment","description":"Count of eyes with retinal tears or detachments during the course of follow-up.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Eyes With Endophthalmitis","description":"Count of eyes with an occurrence of endophthalmitis","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Proportion of Eyes With Severe Vision Loss","description":"Cumulative proportion of eyes with uveitic macular edema who experience severe vision loss (\\>= 15 standard letters) during the 24 weeks of follow-up.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":null},{"groupId":"OG001","value":"0.10","spread":null},{"groupId":"OG002","value":"0.05","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Proportion of Eyes With an IOP Elevation of >=10 mm Hg Over Baseline","description":"Cumulative proportion of eyes with uveitic macular edema that experience an IOP elevation of \\>=10 mm Hg higher than the baseline level during 24 weeks of follow-up.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.14","spread":null},{"groupId":"OG001","value":"0.26","spread":null},{"groupId":"OG002","value":"0.39","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Proportion of Eyes With an IOP Elevation >=24 mm Hg","description":"Cumulative proportion of eyes with uveitic macular edema that experience elevated IOP to \\>=24 mm Hg during 24 weeks of follow-up.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.20","spread":null},{"groupId":"OG001","value":"0.30","spread":null},{"groupId":"OG002","value":"0.41","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Proportion of Eyes With an IOP Elevation >=30 mm Hg","description":"Cumulative proportion of eyes with uveitic macular edema that experience elevated IOP to \\>=30 mm Hg during 24 weeks of follow-up.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":null},{"groupId":"OG001","value":"0.06","spread":null},{"groupId":"OG002","value":"0.04","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":65},"commonTop":[]}}}